GLOW and KLOW are multi-component research blends, and the difference between them is one peptide. GLOW holds three compounds. KLOW holds the same three plus KPV. That single addition changes which questions the vial can support, so it is worth knowing what each component brings to the literature before choosing between them.
What is in each vial
- GLOW is GHK-Cu, BPC-157 and TB-500, freeze-dried together in one vial.
- KLOW is KPV, GHK-Cu, BPC-157 and TB-500, freeze-dried together in one vial. The leading K is the KPV.
Both are co-lyophilized, meaning the components are combined in solution and freeze-dried as a single cake rather than mixed afterwards. Every draw from a reconstituted vial therefore contains all the components in exactly the label ratio.
The three shared components
GHK-Cu. A copper-bound tripeptide, glycyl-L-histidyl-L-lysine, first described in human plasma in the early 1970s. The literature associates it with collagen synthesis in cultured fibroblasts, with changes in matrix metalloproteinase expression, and with broad gene-expression shifts in transcriptome profiling studies. It is also what makes a GLOW or KLOW cake appear tinted rather than plain white, since the copper complex is blue. Full background is in our GHK-Cu article.
BPC-157. A fifteen-residue fragment of a human gastric protein. The preclinical literature associates it with vascular endothelial growth factor receptor 2 signalling, with the nitric oxide system, and with growth factor expression in rodent injury models. Background in what is BPC-157.
TB-500. The acetylated heptapeptide Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln at 889.02 daltons, a synthetic copy of the actin-binding segment at residues 17 to 23 of thymosin beta-4. The endpoints associated with the parent protein are cell migration and cytoskeletal remodelling. Background in what is TB-500.
The rationale for the three together is that they sit at different points of the same general process as it is described in the literature. Matrix and remodelling, vascular and signalling environment, cell movement. That is a design rationale, not a demonstrated synergy, and it should be described that way in any write-up.
The fourth component: KPV
KPV is the shortest peptide in the catalogue, three residues, lysine-proline-valine. It is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Alpha-MSH is a thirteen-residue hormone with a long research history in pigmentation and in inflammation, and work through the 1990s and 2000s established that much of its anti-inflammatory activity in models could be reproduced by the final three residues alone, without the pigmentation-associated activity of the full sequence.
That separation is the reason KPV exists as a research compound. The published models are largely inflammation models. Reports describe reduced inflammatory markers in murine colitis models, uptake into intestinal epithelial cells through the peptide transporter PepT1, and effects on inflammatory signalling in cell culture. None of it concerns human outcomes.
So the difference between the two blends is an inflammation-associated component. A lab studying the matrix and migration side of a model may not need it. A lab whose model has an inflammatory component may want it in the same vial.
Side by side
| Component | In GLOW | In KLOW | Associated in the literature with |
|---|---|---|---|
| GHK-Cu | Yes | Yes | Collagen synthesis, matrix remodelling, gene expression |
| BPC-157 | Yes | Yes | VEGFR2, nitric oxide system, growth factor expression |
| TB-500 | Yes | Yes | Actin sequestration, cell migration |
| KPV | No | Yes | Inflammation models, PepT1 uptake, alpha-MSH derived activity |
Reading the label and doing the math
A blend label states the milligram content of each component separately, not a single total. A four-component vial has four numbers on it. Reconstitution math is then the ordinary calculation, concentration equals mass divided by volume, run once per component.
- A vial listing 10 mg of one component and 5 mg of another, reconstituted with 2 mL, gives 5 mg/mL and 2.5 mg/mL respectively.
- Total solids in that vial are 15 mg, but the total is not a useful working number and should stay out of the notebook.
- Record every component on its own line with its own concentration. A four-component vial means four lines.
- The ratio is fixed at manufacture and cannot be adjusted inside the vial.
Note that a blend containing GHK-Cu inherits its handling quirks, including pH sensitivity and the risk of a chelating buffer stripping the copper, so the diluent should be chosen with that in mind.
When separate vials are the better format
A co-lyophilized blend fixes the ratio, which removes the ability to run a single-component control or to vary one component against the others. Any design that needs those arms needs the components as separate vials. Two bundles exist for exactly that reason. Every component is also sold as a single vial, so a lab can run the arms it needs. The GLOW Bundle pairs the Glow Mix vial with a full GHK-Cu 100 mg vial and KPV 10 mg, and the KLOW Elite Bundle pairs the Klow Blend vial with extra BPC-157 5 mg and GHK-Cu 100 mg. They sit in the bundles collection alongside the rest of the multi-vial sets, while the co-lyophilized vials sit in the blends collection. The same trade-off applies to the two-component pairing, covered in why labs pair BPC-157 and TB-500.
Certificates for multi-component vials
A blend certificate has to resolve every component. Expect a purity figure and a mass-spectrometry identity confirmation for each one, plus the stated mass of each component in the vial. A single purity number printed on a four-component product does not describe anything, because the chromatogram is supposed to contain four peaks. Every lot we release is tested by an independent laboratory for HPLC purity and mass-spec identity, and certificates are available on request.
Frequently asked questions
Is KLOW simply a better version of GLOW?
No. It is a different tool. KLOW adds a component associated with inflammation models in the literature. If the model being run has no inflammatory endpoint, the fourth component adds a variable without adding information.
What does the K in KLOW stand for?
KPV, the lysine-proline-valine tripeptide. GLOW is the same blend without it.
Why is KPV studied separately from alpha-MSH?
Because the published work reported that the anti-inflammatory activity seen in models could be reproduced by the final three residues alone, separated from the pigmentation-associated activity of the full thirteen-residue hormone. That separation is what makes the tripeptide useful as a research tool.
References
- Pickart L and Margolina A, 2018. International Journal of Molecular Sciences. Regenerative and protective actions of the GHK-Cu peptide.
- Dalmasso G and colleagues, 2008. Gastroenterology. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation.
- Kannengiesser K and colleagues, 2008. Inflammatory Bowel Diseases. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease.
- Goldstein AL, Hannappel E and Kleinman HK, 2005. Trends in Molecular Medicine. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues.
- Sikiric P and colleagues, 2011. Current Pharmaceutical Design. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract.
Research use only. This article describes preclinical literature and laboratory handling. Homegrown Peptides products are not for human or animal use, are not drugs, and are not intended to diagnose, treat, cure or prevent any disease. Nothing here is medical advice or a protocol.
